###begin article-title 0
###xml 87 109 87 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 87 108 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Polymorphism and epitope sharing between the alleles of merozoite surface protein-1 of Plasmodium falciparum among Indian isolates
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 284 306 284 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 424 427 424 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 488 491 488 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 646 649 646 649 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 284 305 <span type="species:ncbi:5833">Plasmodium falciparum</span>
The C-terminal region of merozoite surface protein-1 (MSP-1) is one of the leading candidates for vaccination against the erythrocytic stages of malaria. However, a major concern in the development of MSP-1 based malaria vaccine is the polymorphism observed in different geographical Plasmodium falciparum isolates. To explore whether the sequence heterogeneity of PfMSP-1 leads to variation in naturally acquired anti-MSP-119 antibodies, the present study was undertaken to study PfMSP-119 sequence polymorphism in malaria-endemic villages in eastern India and also carried out a competition enzyme-linked immunosorbent assay using three PfMSP-119 variant forms.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 59 62 59 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 120 123 120 123 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 149 166 149 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 173 175 173 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 189 191 189 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 208 210 208 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 149 165 <span type="species:ncbi:562">Escherichia coli</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
The sequence variations in the C-terminal region of PfMSP-119 were determined in a malaria endemic region. Three PfMSP-119 variants were produced in Escherichia coli (PfMSP119QKNG-L, PfMSP119EKNG-L and PfMSP119ETSR-F) and an immunodepletion assay was carried out using the corresponding patients' sera.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 90 93 90 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 171 174 171 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 206 214 206 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 206 213 <span type="species:ncbi:562">E. coli</span>
###xml 307 314 <span type="species:ncbi:9606">patient</span>
Results revealed predominance of PfMAD20 allele among Indian field isolates. Seven PfMSP-119 variant forms were isolated in a singe geographical location. Three of PfMSP-119 variant forms when expressed in E. coli showed presence of cross-reaction as well as variant specific antibodies in malaria infected patient sera.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 78 91 78 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 252 255 252 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 78 91 <span type="species:ncbi:5833">P. falciparum</span>
###xml 101 108 <span type="species:ncbi:9606">patient</span>
The present study demonstrates the existence of allele specific antibodies in P. falciparum-infected patient sera, however their role in protection requires further investigation. These results thereby, suggest the importance of a multi-allelic PfMSP-119 based vaccine for an effective malaria control.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 436 439 436 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">msp</italic>
###xml 695 697 695 697 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 741 742 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 743 744 743 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 789 792 789 792 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 801 803 801 803 <sub xmlns:xlink="http://www.w3.org/1999/xlink">42</sub>
###xml 888 889 888 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 951 954 951 954 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 957 978 957 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 1047 1056 1047 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1080 1082 1080 1082 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 1213 1215 1213 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1216 1218 1216 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 808 812 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 957 978 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 988 993 <span type="species:ncbi:9606">human</span>
Malaria is one of the major causes of death from infection in developing countries. Development of an effective malaria vaccine may reduce malaria-associated severe morbidity and mortality in malaria-endemic areas. A number of parasite surface antigens of asexual blood stages are being investigated as vaccine candidate antigens. [1,2]. Among these antigens, merozoite surface protein-1 (MSP-1) is a leading candidate antigen [3]. The msp-gene encodes a 195 kDa protein that is cleaved in four distinct fragments (83, 28-30, 38-45 and 42 kDa) at the time of schizont rupture. During merozoite invasion, the carboxy-terminal 42-kDa fragment is further processed to yield a 19-kDa fragment (MSP-119) which remains associated with merozoites [4,5]. A number of vaccination studies with MSP-119 and MSP-142, in mice and monkeys have shown partial and full protection from malaria infection [6-11]. A substantial proportion of antibodies directed to MSP-119 in Plasmodium falciparum-infected human sera have been shown to inhibit erythrocyte invasion in vitro [12]. Importantly, MSP-119-mediated protective immune responses are largely antibody dependent with high antibody titres being essential for the protection [13,14].
###end p 11
###begin p 12
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">msp-1 </italic>
###xml 13 27 13 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 120 140 120 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum msp-1 </italic>
###xml 250 256 250 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">msp-1 </italic>
###xml 350 351 350 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 529 534 529 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">msp-1</italic>
###xml 558 561 558 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 602 603 602 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 885 887 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 949 952 944 947 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 988 1002 983 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 1126 1129 1121 1124 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 1171 1173 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1174 1176 1169 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1177 1179 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 13 26 <span type="species:ncbi:5833">P. falciparum</span>
###xml 120 133 <span type="species:ncbi:5833">P. falciparum</span>
###xml 988 1001 <span type="species:ncbi:5833">P. falciparum</span>
The msp-1 of P. falciparum has been shown to be dimorphic, K1/Wellcome and MAD 20 types [15,16]. Sequence comparison of P. falciparum msp-1 sequences among different geographical isolates shows a great deal of variations. Based on sequence analysis, msp-1 has been divided into 17 blocks comprising of conserved, semi conserved and variable regions [5,15]. Intragenic recombination between the two allelic types appears to be the main cause for variability among different field isolates [16-18]. The C-terminal 19 kDa region of msp-1, that represents the 17th block, consists of two EGF like domains [5] and has been shown to be highly conserved among different isolates, with single amino acid substitution at five different positions. These changes are E mu Q at position 1644 in the first EGF domain and at positions, 1691 (T mu K), 1700 (S mu N), 1701 (R mu G) and 1716 (L mu F) [19]. Based on these variations, several variant forms of PfMSP-119 have been described among different P. falciparum isolates around the world. However, there are a limited number of reports of genetic diversity of C-terminal region of MSP-119 in isolates from the Indian subcontinent [18,20,21], that contribute around two million cases every year (Source: National Vector Borne Disease Control Programme).
###end p 12
###begin p 13
###xml 59 62 59 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 256 259 256 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
The present study investigated sequence variations in MSP-119 region among different field isolates from a malaria endemic area in India. This study reveals existence of seven variant types in a single geographical location. In addition, three of the MSP-119 variants, Q-KNG-L, E-KNG-L and E-TSR-F were expressed and the relative abundance of specific antibodies in their respective sera studied.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 14 28 14 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 14 27 <span type="species:ncbi:5833">P. falciparum</span>
Collection of P. falciparum infected blood and sera
###end title 15
###begin p 16
###xml 0 14 0 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 702 716 702 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 918 920 918 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 0 13 <span type="species:ncbi:5833">P. falciparum</span>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
###xml 562 570 <span type="species:ncbi:9606">patients</span>
###xml 621 628 <span type="species:ncbi:9606">infants</span>
###xml 702 715 <span type="species:ncbi:5833">P. falciparum</span>
P. falciparum infected blood samples were collected on filter paper by finger prick from malaria patients participating in cross-sectional and longitudinal malaria epidemiology surveys being conducted in malaria endemic villages in Sundergarh district, Orissa in eastern India [23]. Thirteen study villages were chosen, out of which eight villages were located in deep forests and five villages were located in plain areas. Prior consent of the patients and the consent of institutional ethical committee were taken before the beginning of the study. Age of the patients ranged between six months to 17 years. In case of infants, the consent of parents were obtained. All the samples were positive for P. falciparum infection as determined by Giemsa-stained thick smears examined microscopically. Sixteen field spots were chosen from six different villages and DNA was isolated from these spots by the boiling method [24]. Blood samples were also collected and allowed to clot at room temperature, and serum was collected by centrifugation at 2,000 rpm for 10 min at 4degreesC and stored at -20degreesC until used.
###end p 16
###begin title 17
PCR amplification, cloning and sequencing
###end title 17
###begin p 18
###xml 49 52 49 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 152 166 151 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 152 165 <span type="species:ncbi:5833">P. falciparum</span>
To determine the sequence polymorphism in PfMSP-119 gene, PCR amplification was done in a 50 mul reaction volume using 10 ng genomic DNA from different P. falciparum isolates and primers MSP1-19F1 (Forward: 5' ATT GAG ACC TTA TAC AAT AAC 3') and MSP1-19R1 (Reverse: 5' TTA AGG TAA CAT ATT TTA ACT CCT AC 3'). The thermocycler profile was 5 min hot start at 94degreesC and 30 cycles each of 30 sec at 94degreesC, 1 min at 50degreesC and 30 sec at 72degreesC. In some cases, nested PCR was employed using a second set of forward primer MSP1-19F2 (Forward: 5' GAT ACG AAA AAA GAT ATG CTT GG 3') and the same reverse primer. The amplified PCR products (480 bps) were analysed by agarose gel electrophoresis and purified by QIAquick Gel Extraction Kit (Qiagen). The purified PCR fragments were cloned into pGEM-T cloning vector as per manufacturer's instructions (Promega). The positive clones were selected by restriction enzyme analysis. Three independent clones from a minimum of two PCR amplifications for each isolate were sequenced using T7 forward and M13 reverse primers.
###end p 18
###begin title 19
###xml 44 47 44 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
Expression and purification of three PfMSP-119 variants
###end title 19
###begin p 20
###xml 29 32 29 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 86 89 86 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 252 255 252 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 262 265 262 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sal</italic>
###xml 391 394 391 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 430 447 430 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 488 491 488 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 430 446 <span type="species:ncbi:562">Escherichia coli</span>
For the expression of PfMSP-119 variants, the 288-bp fragment corresponding to PfMSP-119 region were amplified using primers; 5'-GACTAGGGATCCATTTCACAACACCAATGCG-3' and 5'-GCTGATGTCGACTTAGTTAGAGGAACTGCAGAA-3' and cloned into pQE-30 expression vector in BamHI and SalI sites. This vector provides six His residues at the N terminus of the expressed protein. Expression of the recombinant MSP-119 was induced with 0.5 mM IPTG in the Escherichia coli strain M15. For the purification of MSP-119 proteins, the induced pellets were sonicated in 1 x TBS (Tris 50 mM, NaCl 500 mM), pH 8.0 containing 1 mM PMSF and 0.05% Tween 20. The supernatant containing the expressed proteins were incubated with Nickel-NTA-Agarose for 1 h at room temperature. The resins were washed with 1 x TBS containing 10 mM imidazole. The bound proteins were eluted with an imidazole gradient of 20 to 250 mM at pH 8.0. Q-KNG-L variant was eluted with a linear gradient of 10 to 70 mM Imidazole in 20 mM Tris-500 mM NaCl (pH 8.0) buffer, E-KNG-L variant was eluted in a linear gradient of 50-250 mM and E-TSR-F was eluted in 250 mM Imidazole. The eluates were analysed by SDS-PAGE, the fractions containing a clear single protein band were pooled, and the protein concentrations were determined.
###end p 20
###begin title 21
ELISA
###end title 21
###begin p 22
###xml 37 40 37 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 219 222 219 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 858 859 852 853 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 860 862 854 856 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 918 919 912 913 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 921 922 915 916 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 54 61 <span type="species:ncbi:9606">patient</span>
###xml 556 563 <span type="species:ncbi:9606">patient</span>
###xml 627 638 <span type="species:ncbi:3704">horseradish</span>
Reactivity of the recombinant PfMSP-119 proteins with patient sera was evaluated by ELISA as described earlier [25]. Briefly, 96-well microplates (Dynatech) were coated with 50 ng of any of the three recombinant PfMSP-119 proteins per well in 0.06 M carbonate-bicarbonate buffer (pH 9.6). The plates were incubated overnight at 4degreesC, and the wells were blocked with 5% low-fat milk in PBS (pH 7.2) for 1 h at room temperature. The antigen-coated wells were sequentially incubated with serial dilutions (starting from 1:50 dilutions) of the individual patient sera and optimally diluted enzyme-labelled secondary antibody (horseradish peroxidase-labeled antihuman immunoglobulin, IgG). In between these incubations, the plates were washed with a 0.05% solution of Tween 20 in PBS. The enzyme reaction was developed with o-phenylediamine dihydrochloride-H2O2 in citrate phosphate buffer (pH 5.0), stopped with 8 N H2SO4, and recorded at 490 nm by use of a microplate reader (Molecular Devices).
###end p 22
###begin title 23
Antibody depletion assay
###end title 23
###begin p 24
###xml 72 75 72 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 86 99 86 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 282 285 282 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 320 322 320 322 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 336 338 336 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 355 357 355 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 630 643 630 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 1460 1463 1460 1463 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 1479 1481 1479 1481 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 1508 1510 1508 1510 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 86 99 <span type="species:ncbi:5833">P. falciparum</span>
###xml 109 114 <span type="species:ncbi:9606">human</span>
###xml 630 643 <span type="species:ncbi:5833">P. falciparum</span>
###xml 653 658 <span type="species:ncbi:9606">human</span>
To determine the relative abundances of antibodies specific for a PfMSP119 variant in P. falciparum-infected human sera, an antibody depletion assay was carried out as described earlier [25]. The wells of flat-bottom Immunolon-2 plates were coated with 100 ng of each of the PfMSP-119 recombinant antigens, namely PfMSP119QKNG-L, PfMSP119EKNG-L and PfMSP119ETSR-F. The wells were blocked with 5% low-fat milk in PBS (pH 7.2) for 1 h at room temperature. After blocking, all of the wells were washed with 0.05% Tween 20 in PBS and then with PBS (pH 7.2), the first two wells in the first column were incubated for ten minutes with P. falciparum-infected human sera of the respective sequence variants at a dilution of 1:100, while the remaining wells contained only wash buffer. The sera from the first two wells were transferred to the next respective wells in the second column and incubated for half an hour. These serial incubations were carried out until all of the antibodies with respect to a particular antigen were depleted, as determined by color development in the wells by a standard ELISA. It was observed that for all the sequence variantss, antigen-specific antibodies were completely removed from the respective sera after six serial transfers except in the case of Q-KNG-L variant which depleted the sera after nine serial transfers. All these antibody-depleted sera were subsequently analysed for their cross reactivity with each of the PfMSP119 variants; PfMSP119Q-KNG-L, E-KNG-L and PfMSP119E-TSR-F antigens by ELISA. The reactivity of each protein with the other two depleted sera was compared with the undepleted sera to analyse the relative contribution of each antigen.
###end p 24
###begin title 25
Results
###end title 25
###begin title 26
Epidemiology of malaria transmission in malaria endemic villages in Orrisa, India
###end title 26
###begin p 27
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 386 408 386 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 515 529 515 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 781 803 781 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Anopheles fluvialitis </italic>
###xml 807 830 807 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Anopheles culicifacies </italic>
###xml 1123 1137 1123 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. fluvialitis</italic>
###xml 386 407 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 515 528 <span type="species:ncbi:5833">P. falciparum</span>
###xml 713 721 <span type="species:ncbi:9606">children</span>
###xml 807 829 <span type="species:ncbi:139723">Anopheles culicifacies</span>
###xml 1015 1021 <span type="species:ncbi:9606">person</span>
###xml 1310 1318 <span type="species:ncbi:9606">patients</span>
###xml 1356 1364 <span type="species:ncbi:9606">patients</span>
Thirteen study villages were chosen, out of which eight villages were located in deep forests and five villages were located in plain areas. A detailed study of the epidemiology of malaria transmission was done in these villages from January 2001 to December 2003 and was reported [26]. Briefly, malaria transmission is perennial but is markedly low in the plain area than forest area. Plasmodium falciparum accounted for 85% of total malaria cases during the study period. In forest and plain areas, the number of P. falciparum cases per thousand populations were 284.1 and 31.2 respectively, whereas the parasite rate was 14% and 1.7% respectively. In forest areas, clinical malaria occurred more frequently in children aged 0-5 years and declined gradually with increasing age. Anopheles fluvialitis and Anopheles culicifacies were the two vector species responsible for malaria transmission in these villages. The entomological inoculation rate in the forest and plain areas was 0.311 and 0.014 infective bites/person/night, respectively during 2003. The peak of malaria incidence coincided with peak vector density of A. fluvialitis, suggesting that this is the predominant vector for malaria transmission in these villages. Parasite density with a geo mean density of more than 2000 were detected in 211 patients in the forest area as compared to 28 patients in the plain area.
###end p 27
###begin title 28
###xml 32 35 32 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
Sequence polymorphism in PfMSP-119 gene
###end title 28
###begin p 29
###xml 48 51 48 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 78 92 78 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 132 135 132 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 159 162 159 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 246 260 246 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 502 505 502 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 708 711 708 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 78 91 <span type="species:ncbi:5833">P. falciparum</span>
###xml 246 259 <span type="species:ncbi:5833">P. falciparum</span>
To determine the extent of polymorphism of MSP-119 in a natural population of P. falciparum in India, the C-terminal region of MSP-119 gene corresponding to 16th block (a variable region) and 17th block (a conserved region) was amplified from 16 P. falciparum isolates. The amplified fragments were sequenced and these sequences were compared with that of two prototypic alleles, MAD20 and K1/Wellcome (Figure 1). Comparison of the sequences between 1594 and 1630 aa that correspond to the 3' end of 16th block, showed that all these field isolates belong to one of the two prototypic alleles, MAD20. Existence of both allelic forms in a single isolate was not observed. All the sequences corresponding to 16th block were highly conserved; only a few variations were seen in two of the 16 isolates. A change K mu R was observed at amino acid position 1603 in one of the isolate, BM8-55. These results suggested the predominance of MAD 20 allelic type among these field isolates in India.
###end p 29
###begin p 30
###xml 82 96 82 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 82 95 <span type="species:ncbi:5833">P. falciparum</span>
Sequence diversity in the C-terminal region (blocks 16 and 17) of MSP-1 in Indian P. falciparum isolates in a single geographical location.
###end p 30
###begin p 31
###xml 336 337 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 607 609 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 648 650 643 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 835 836 830 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1085 1087 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1252 1254 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1255 1257 1248 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 803 810 <span type="species:ncbi:9606">patient</span>
In block 17 which represents the C-terminal, cysteine-rich 19 kDa fragment of MSP-1 (1631-1744), the nucleotide and the deduced amino acid sequences were found to be highly conserved with only five substitutions seen at positions, 1644 (E mu Q), 1691 (T mu K), 1700 (S mu N), 1701 (G mu R) and 1716 (L mu F) among Indian isolates (Fig. 1). All the nucleotide changes in these isolates were non-synonymous, as a result, the deduced amino acid variation corresponded to one or other allele. Based on these five changes, seven different allelic forms were identified, many of which have been reported earlier [19]. Among the several alleles of PfMSP-119, Q-KNG-L allele was seen in 5/16 isolates, while E-KNG-L and E-TSR-L alleles were observed in 3/16 isolates. Existence of two allelic forms in a single patient was not observed. Table 1 shows the distribution of different allelic types among theses Indian isolates. In addition to the reported combinations of the allele determining residues, we observed two novel allelic forms, E-TSR-F and E-TNR-L that have been predicted earlier [19]. Few other substitutions was seen in one of the isolate BM8-32, at positions 1701 (K mu Q) and 1710 (K mu N). Changes as reported in other geographical locations [19,27] were not observed among these Indian isolates.
###end p 31
###begin p 32
###xml 23 26 23 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 61 75 61 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 61 74 <span type="species:ncbi:5833">P. falciparum</span>
Distribution of PfMSP-119 allelic types identified in Indian P. falciparum isolates.
###end p 32
###begin title 33
###xml 27 30 27 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
Expression of three PfMSP-119 variants and epitope sharing among these isolates
###end title 33
###begin p 34
###xml 21 24 21 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 120 134 120 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 269 272 269 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 362 365 362 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 415 418 415 418 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 547 563 547 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 581 584 581 584 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 779 781 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 120 133 <span type="species:ncbi:5833">P. falciparum</span>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
###xml 547 563 <span type="species:ncbi:562">Escherichia coli</span>
The sequenced PfMSP-119 gene fragment corresponding to three variant types (Q-KNG-L, E-KNG-L and E-TSR-F) isolated from P. falciparum infected patients (BK-62, PP3-18 and CM3-56) were cloned into pQE-30 vector and expression was induced with IPTG. All the three PfMSP-119 variants were expressed in soluble form and the proteins were purified up to 85% by Ni-NTA2+ chromatography. The three variant forms of PfMSP-119 migrated as a single major band on SDS-PAGE under reducing conditions and had apparent molecular mass of ~17-19 kDa (Figure 2A). Escherichia coli-expressed PfMSP-119 variants were recognized by monoclonal antibody, 12.10 and a polyclonal antibody raised against Q-KNG-L variant type (Figures 2B and 2C). These results were in accordance with previous findings [28].
###end p 34
###begin p 35
###xml 38 46 38 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 63 66 63 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 149 152 149 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 223 226 223 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 290 293 290 293 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 38 45 <span type="species:ncbi:562">E. coli</span>
Expression and immunoblot analysis of E. coli expressed PfMSP-119 variants. (a) Coomassie blue-stained 12% SDS-polyacrylamide gel of purified PfMSP-119 variants. (b & c) Immunoblot analysis to show the reactivity of PfMSP-119 variants with monoclonal antibodies (12.10) and with anti-PfMSP119 (Q-KNG-L) antibody.
###end p 35
###begin p 36
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 545 558 545 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 795 798 795 798 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 832 833 832 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1196 1199 1196 1199 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 1363 1366 1363 1366 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 1442 1445 1442 1445 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 1496 1510 1496 1510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
###xml 321 328 <span type="species:ncbi:9606">patient</span>
###xml 545 558 <span type="species:ncbi:5833">P. falciparum</span>
###xml 568 576 <span type="species:ncbi:9606">patients</span>
###xml 854 861 <span type="species:ncbi:9606">patient</span>
###xml 1239 1247 <span type="species:ncbi:9606">patients</span>
###xml 1496 1509 <span type="species:ncbi:5833">P. falciparum</span>
###xml 1519 1527 <span type="species:ncbi:9606">patients</span>
To examine the cross-reactive epitopes in the three variant types, an ELISA assay was carried out using their respective sera and with sera obtained from patients showing other variant types. As shown in Figure 3, the three variant types showed reactivity with each sera; however the extent of reactivity varied with the patient sera. To determine the contribution of variant specific epitopes in the generation of an immune response during a natural infection, an immunodepletion assay was carried out. For the ELISA depletion assay, sera from P. falciparum-infected patients were absorbed with either of the variant recombinant proteins in such a way that all of the antigen specific antibodies were lost. The reactivity of the sera depleted was further analysed with all the expressed PfMSP-119 variant forms. As shown in Figure 4, when the sera from patient, BK3-62 expressing Q-KNG-L variant type was depleted with either Q-KNG-L or E-KNG-L or E-TSR-F proteins, there was < 90% reduction in reactivity of the depleted sera with Q-KNG-L antigen in comparison to its reactivity with undepleted sera. These depleted sera also showed a reduction of ~40-50% in its reactivity to other two PfMSP-119 variant types. Likewise, when sera from patients, PP3-18 expressing E-KNG-L variant type and CM3-56 expressing E-TSR-F was depleted with either of the three PfMSP-119 variant forms, similar reduction was seen. These results showed that PfMSP-119 variant specific immune responses are generated in P. falciparum infected patients.
###end p 36
###begin p 37
###xml 21 24 21 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 70 84 70 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 70 83 <span type="species:ncbi:5833">P. falciparum</span>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Reactivity of PfMSP-119 variants in an ELISA with sera collected from P. falciparum infected patients at a dilution of 1:200. Error bars indicate S.D.
###end p 37
###begin p 38
###xml 52 55 52 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 95 109 95 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 95 108 <span type="species:ncbi:5833">P. falciparum</span>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
Immunodepletion assay showing the presence of PfMSP119 allele specific antibodies in sera from P. falciparum infected patients. Error bars indicate S.D.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 33 36 33 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 128 141 128 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 300 314 300 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 490 492 490 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 653 656 653 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 736 738 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 128 141 <span type="species:ncbi:5833">P. falciparum</span>
###xml 300 313 <span type="species:ncbi:5833">P. falciparum</span>
Sequence heterogeneity in PfMSP-119 protein, a leading vaccine candidate antigen for vaccination against erythrocytic stages of P. falciparum, may compromise its use as a vaccine candidate antigen. Based on sequence variations among different laboratory and field isolates, two prototypic alleles of P. falciparum MSP-1 represented by PfMAD20 and PfK1/Wellcome have been described in isolates from Africa, Asia and Latin America [15,16,24,25]. The C-terminal 19 kDa region of MSP-1 (PfMSP-119) is a highly conserved region showing amino-acid alterations at only five positions out of 102 residues. Based on these alterations, about ten different PfMSP-119 allelic forms have been predicted in different field isolates across the world [19].
###end p 40
###begin p 41
###xml 33 36 33 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 57 71 57 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 273 275 273 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 312 315 312 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 601 604 601 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 661 664 661 664 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 57 70 <span type="species:ncbi:5833">P. falciparum</span>
Here, sequence diversity in MSP-119 region, among Indian P. falciparum field isolates in malaria endemic villages in same geographical location was investigated. Some of these isolates have been previously analysed for sequence variations in the receptor binding domain of PfEBA-175 [29]. Sequence data of the 16th block of MSP-1 revealed that all the isolates were of PfMAD20 type. The present study's results and the data obtained from previous studies clearly demonstrate that MAD20 allelic form predominates among Indian PfMSP-1 isolates from different geographical locations [18,20,30]. In the 17th block, seven allelic forms was observed. Of these PfMSP-119 alleles, two alleles (E-TNR-L & E-TSR-F) have not been reported earlier, however, Qari et al (1998) have earlier predicted E-TNR-L. These allelic forms seem to have generated due to intragenic recombination between the two prototypic alleles as suggested earlier because all the substituted amino acids belonged to either one or other allelic form.
###end p 41
###begin p 42
###xml 66 69 66 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 122 136 122 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 168 171 168 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 230 238 230 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 314 316 314 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 350 353 350 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 462 465 462 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 566 569 566 569 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 747 750 747 750 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 1212 1214 1212 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 122 135 <span type="species:ncbi:5833">P. falciparum</span>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 230 237 <span type="species:ncbi:562">E. coli</span>
###xml 534 539 <span type="species:ncbi:4932">yeast</span>
To know whether these five amino acid substitutions in the PfMSP-119 region generate variant specific immune responses in P. falciparum infected patients, three PfMSP-119 variants (Q-KNG-L, E-KNG-L & E-TSR-F) were expressed in an E. coli expression system with an N-terminal His tag. Proteins were purified on a Ni2+-NTA column. All the three PfMSP-119 recombinant forms were recognized well by an invasion inhibitory monoclonal antibody (12.10) and anti-PfMSP-119 (Q-KNG-L) polyclonal antibody. An earlier study [28] showed that the yeast secreted recombinant MSP-119 variants are recognized by polyclonal antibody raised against baculoproduced MSP1 (E-KNG) variant and by mAB 5B1 that is known to inhibit invasion. Recognition of all the PfMSP-119 variants by mAB 5B1 and 12.10 suggest that some of these protective epitopes are not variant specific. A preliminary investigation of protective type IgG1/IgG3 antibody response to Q-KNG-L sequence variant was carried out and significant IgG1/IgG3 responses were observed in the infected sera (data not shown). The frequency of IgG1 responses in different sera was quite similar while a significant difference was seen within IgG3 responses as previously shown [31].
###end p 42
###begin p 43
###xml 314 328 314 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 390 393 390 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 841 844 841 844 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 937 939 937 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 940 942 940 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1093 1094 1093 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1095 1097 1095 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 314 327 <span type="species:ncbi:5833">P. falciparum</span>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
###xml 812 816 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 854 858 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
To determine the presence of variant specific antibodies during the natural infection, sera from BK3-62, CM3-56 and PP3-18 patients were immuno-depleted using each of the three recombinant antigens and the depleted sera were analysed for reactivity with three variant antigens. Results demonstrated that sera from P. falciparum infected patients do contain cross-reactive as well as PfMSP-119 variant specific antibodies. At present, it is difficult to say up to what extent these variant specific antibodies contribute to protective immune responses. Another aspect that requires probing is the contribution of historic infections with parasite of different sequence types. However, data from a number of challenge studies have also provided evidences for the variant specific immune responses. Immunization of mice with recombinant PyMSP-119 protected mice against homologous but not heterologous sporozoite or blood stage challenges [32,33]. In some cases where some level of protection to heterologous malarial challenge was seen, it was significantly lower than the homologous challenge [6,34].
###end p 43
###begin title 44
Conclusion
###end title 44
###begin p 45
###xml 140 143 140 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 363 366 363 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 385 399 385 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 462 465 462 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 593 606 593 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 718 721 718 721 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 903 906 903 906 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 385 398 <span type="species:ncbi:5833">P. falciparum</span>
###xml 416 421 <span type="species:ncbi:9606">human</span>
###xml 593 606 <span type="species:ncbi:5833">P. falciparum</span>
In summary, the present study has shown that PfMAD 20 is the major PfMSP-1 allelic form present in Indian population and a number of PfMSP-119 allelic forms exist even in a single geographical location in a malaria-endemic region in India. The present study further show that significant levels of cross reactive antibodies are generated against different PfMSP-119 allelic forms in a P. falciparum infected natural human population. However, presence of PfMSP-119 allele specific antibodies was also observed in this population thus suggesting, for a better protection against all strains of P. falciparum, it will be appropriate to use a vaccine containing all possible sequence variants. Although only three PfMSP-119 variants were expressed and subsequently analysed for the presence of specific antibodies in the present study, a detailed study is required to clearly understand the role of PfMSP-119 variants in eliciting a protective immune response.
###end p 45
###begin title 46
Authors' contributions
###end title 46
###begin p 47
AM carried out polymorphism studies, SS expressed the proteins and carried out the ELISAs and depletion assays. Both AM and SS contributed equally in the study. SSD participated in depletion assays, SKS was involved in sample collection, PKT participated in sample collection, TA provided with sera samples, HJ handled sequence data, PM participated in design and coordination of the project along with drafting the manuscript. All authors read and approved the final manuscript.
###end p 47
###begin title 48
Acknowledgements
###end title 48
###begin p 49
We are grateful to those who donated blood for this study. This work is supported by grants from Vaccine Mission Programme, Department of Biotechnology, Government of India and World Health Organization.
###end p 49
###begin article-title 50
Progress and challenges for malaria vaccines
###end article-title 50
###begin article-title 51
The economic and social burden of malaria
###end article-title 51
###begin article-title 52
Towards a blood-stage vaccine for malaria: are we following all the leads?
###end article-title 52
###begin article-title 53
###xml 28 50 28 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 28 49 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1
###end article-title 53
###begin article-title 54
###xml 31 41 31 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium</italic>
Merozoite surface antigen-1 of Plasmodium
###end article-title 54
###begin article-title 55
###xml 85 107 85 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 85 106 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1
###end article-title 55
###begin article-title 56
###xml 24 46 24 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 94 109 94 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aotus nancymai </italic>
###xml 24 45 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 94 108 <span type="species:ncbi:37293">Aotus nancymai</span>
Immunity to recombinant Plasmodium falciparum merozoite surface protein (MSP1): Protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity
###end article-title 56
###begin article-title 57
###xml 42 59 42 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 69 91 69 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 42 58 <span type="species:ncbi:562">Escherichia coli</span>
###xml 69 90 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 127 132 <span type="species:ncbi:9606">human</span>
Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-142 using human compatible adjuvants
###end article-title 57
###begin article-title 58
###xml 63 85 63 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 122 128 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aotus </italic>
###xml 63 84 <span type="species:ncbi:5833">Plasmodium falciparum</span>
A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 2 protects Aotus monkeys against malaria
###end article-title 58
###begin article-title 59
###xml 132 149 132 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium yoelii</italic>
###xml 132 149 <span type="species:ncbi:5861">Plasmodium yoelii</span>
Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii
###end article-title 59
###begin article-title 60
###xml 32 54 32 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 132 149 132 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aotus vociferans </italic>
###xml 32 53 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 132 148 <span type="species:ncbi:57176">Aotus vociferans</span>
Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or, -rechallenged Aotus vociferans monkeys
###end article-title 60
###begin article-title 61
###xml 54 76 54 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 120 128 120 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 54 75 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Human antibodies to the 19 kDa C-terminal fragment of Plasmodium falciparum merozoite protein 1 inhibit parasite growth in vitro
###end article-title 61
###begin article-title 62
Humoral response to a carboxyl-terminal region of the merozoite surface protein 1 plays a predominant role in controlling blood-stage infection in rodent malaria
###end article-title 62
###begin article-title 63
###xml 159 177 159 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium yoelii </italic>
###xml 190 214 190 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae</italic>
###xml 40 44 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 159 176 <span type="species:ncbi:5861">Plasmodium yoelii</span>
###xml 190 214 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-termianl fragment of the merozoite surface protein-1 (MSP[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells
###end article-title 63
###begin article-title 64
###xml 69 90 69 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 69 90 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum
###end article-title 64
###begin article-title 65
###xml 121 142 121 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 121 142 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum
###end article-title 65
###begin article-title 66
###xml 16 33 16 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium vivax </italic>
###xml 16 32 <span type="species:ncbi:5855">Plasmodium vivax</span>
Polymorphism in Plasmodium vivax MSA1 gene- the result of intragenic recombinations?
###end article-title 66
###begin article-title 67
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 0 21 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Plasmodium falciparum variations in the C-terminal cysteine rich region of the merozoite surface protein-1 field samples among Indian isolates
###end article-title 67
###begin article-title 68
###xml 34 56 34 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 34 55 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Predicted and observed alleles of Plasmodium falciparum merozoite surface protein (MSP-1) and a potential malaria vaccine antigen
###end article-title 68
###begin article-title 69
###xml 51 73 51 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 104 110 104 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aotus </italic>
###xml 51 72 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys
###end article-title 69
###begin article-title 70
###xml 61 83 61 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 61 82 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Genetic diversity in the merozoite surface protein 1 gene of Plasmodium falciparum in different malariaendemic localities
###end article-title 70
###begin article-title 71
Epidemiology of malaria transmission and development of natural immunity in a malaria endemic village, San Dulakudar, in Orissa state, India
###end article-title 71
###begin article-title 72
###xml 33 54 33 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 33 54 <span type="species:ncbi:5833">Plasmodium falciparum</span>
PCR and strain identification in Plasmodium falciparum
###end article-title 72
###begin article-title 73
###xml 44 61 44 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium vivax </italic>
###xml 135 151 135 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 44 60 <span type="species:ncbi:5855">Plasmodium vivax</span>
###xml 135 151 <span type="species:ncbi:562">Escherichia coli</span>
Comparison of immunogenicity of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42- Kilodalton Fragments Expressed in Escherichia coli
###end article-title 73
###begin article-title 74
###xml 111 133 111 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 111 132 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Sequence conservation in the Cterminal part of the precursor to the major merozoite surface proteins (MSP1) of Plasmodium falciparum from field isolates
###end article-title 74
###begin article-title 75
Epimediology of malaria transmission in forest and plain ecotype villages in Sundargarh district, Orissa, India
###end article-title 75
###begin article-title 76
###xml 38 60 38 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 38 59 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1)
###end article-title 76
###begin article-title 77
###xml 32 54 32 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 81 83 81 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 108 132 108 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae</italic>
###xml 32 53 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 108 132 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Expression and antigenticity of Plasmodium falciparum major surface protein (MSP119) variants secreted from Saccharomyces cerevisiae
###end article-title 77
###begin article-title 78
###xml 57 79 57 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 57 78 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Sequence polymorphisms in the receptor-binding domain of Plasmodium falciparum EBA-175: Implications for malaria vaccine development
###end article-title 78
###begin article-title 79
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 0 21 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Plasmodium falciparum: Genetic diversity of C-terminal region of MSP-1 in isolates from Indian sub-continent
###end article-title 79
###begin article-title 80
###xml 71 73 71 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19</sub>
###xml 119 141 119 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 119 140 <span type="species:ncbi:5833">Plasmodium falciparum</span>
IgG1/IgG3 antibody responses to various analogs of recombinant yPf MSP119- a study in immune adults living in areas of Plasmodium falciparum transmission
###end article-title 80
###begin article-title 81
###xml 53 71 53 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium yoelii </italic>
###xml 145 155 145 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. yoelii </italic>
###xml 53 70 <span type="species:ncbi:5861">Plasmodium yoelii</span>
###xml 100 104 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 145 154 <span type="species:ncbi:5861">P. yoelii</span>
Immunization with recombinant C-terminal fragment of Plasmodium yoelii merozoite protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge
###end article-title 81
###begin article-title 82
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium</italic>
Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge
###end article-title 82
###begin article-title 83
###xml 63 67 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Protective immunity between malaria parasite and piroplasms in mice
###end article-title 83

